Purple Biotech Q3 net loss widens to $1.3 mln

Reuters11-14

<a href="https://laohu8.com/S/PPBT">Purple Biotech</a> Q3 net loss widens to $1.3 mln

Overview

Purple Biotech Q3 net loss $1.3 mln, up from $0.7 mln last year
Operating loss decreased due to reduced CM24 Phase 2 study expenses
Company has $10.5 mln cash, runway into first half of 2027

Outlook

Company plans to submit IND application and initiate Phase 1 study for IM1240 in 2026
Company expects cash runway to support operations into the first half of 2027

Result Drivers

COST MANAGEMENT - Decrease in R&D expenses mainly due to reduced CM24 Phase 2 study costs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$1.30 mln
Q3 Adjusted Operating Income		-$1.30 mln
Q3 Operating Income		-$1.40 mln

Analyst Coverage

The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Purple Biotech Ltd is $34.00, about 97.8% above its November 13 closing price of $0.74

Press Release: ID:nGNX2NBRdp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583062015?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583062015","market":"fut","top_or_hot":-1,"title":"Purple Biotech Q3 net loss widens to $1.3 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/PPBT\">Purple Biotech</a> Q3 net loss widens to $1.3 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Purple Biotech Q3 net loss $1.3 mln, up from $0.7 mln last year</p></li><li><p>Operating loss decreased due to reduced CM24 Phase 2 study expenses</p></li><li><p>Company has $10.5 mln cash, runway into first half of 2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to submit IND application and initiate Phase 1 study for IM1240 in 2026</p></li><li><p>Company expects cash runway to support operations into the first half of 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COST MANAGEMENT - Decrease in R&amp;D expenses mainly due to reduced CM24 Phase 2 study costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.30 mln</p></td><td></td></tr><tr><td><p>Q3 Adjusted Operating Income</p></td><td></td><td><p>-$1.30 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$1.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Purple Biotech Ltd is $34.00, about 97.8% above its November 13 closing price of $0.74</p></li></ul><p>Press Release: <span>ID:nGNX2NBRdp</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Purple Biotech Q3 net loss widens to $1.3 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPurple Biotech Q3 net loss widens to $1.3 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/PPBT\">Purple Biotech</a> Q3 net loss widens to $1.3 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Purple Biotech Q3 net loss $1.3 mln, up from $0.7 mln last year</p></li><li><p>Operating loss decreased due to reduced CM24 Phase 2 study expenses</p></li><li><p>Company has $10.5 mln cash, runway into first half of 2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to submit IND application and initiate Phase 1 study for IM1240 in 2026</p></li><li><p>Company expects cash runway to support operations into the first half of 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COST MANAGEMENT - Decrease in R&amp;D expenses mainly due to reduced CM24 Phase 2 study costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.30 mln</p></td><td></td></tr><tr><td><p>Q3 Adjusted Operating Income</p></td><td></td><td><p>-$1.30 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$1.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Purple Biotech Ltd is $34.00, about 97.8% above its November 13 closing price of $0.74</p></li></ul><p>Press Release: <span>ID:nGNX2NBRdp</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PPBT","symbol_name":"Purple Biotech Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ0IW:1","article_id":"2583062015","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583062015","pubTimestamp":1763125707,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Purple Biotech Q3 net loss widens to $1.3 mlnOverviewPurple Biotech Q3 net loss $1.3 mln, up from $0.7 mln last yearOperating loss decreased due to reduced CM24 Phase 2 study expensesCompany has $10.5","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PPBT":"Purple Biotech Ltd.","BK4007":"制药"},"translate_title":"紫色生物科技第三季度净亏损扩大至130万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PPBT":0.9},"content_text":"Purple Biotech Q3 net loss widens to $1.3 mlnOverviewPurple Biotech Q3 net loss $1.3 mln, up from $0.7 mln last yearOperating loss decreased due to reduced CM24 Phase 2 study expensesCompany has $10.5 mln cash, runway into first half of 2027OutlookCompany plans to submit IND application and initiate Phase 1 study for IM1240 in 2026Company expects cash runway to support operations into the first half of 2027Result DriversCOST MANAGEMENT - Decrease in R&D expenses mainly due to reduced CM24 Phase 2 study costsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$1.30 mlnQ3 Adjusted Operating Income-$1.30 mlnQ3 Operating Income-$1.40 mlnAnalyst CoverageThe one available analyst rating on the shares is \"buy\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Purple Biotech Ltd is $34.00, about 97.8% above its November 13 closing price of $0.74Press Release: ID:nGNX2NBRdpFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583062015","isCrawlerRequest":true}